CA IL12
Alternative Names: CA-IL12Latest Information Update: 28 Jun 2023
At a glance
- Originator University of California, San Diego
- Developer Cytonus Therapeutics; University of California, San Diego
- Class Antineoplastics; Immunotherapies; RNA
- Mechanism of Action Interleukin 12 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours; Triple negative breast cancer
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (Intratumoural, Injection)
- 28 Jun 2023 No recent reports of development identified for preclinical development in Solid-tumours in USA (Intratumoural, Injection)
- 28 Apr 2023 No recent reports of development identified for preclinical development in Triple-negative-breast-cancer in USA (Intratumoural, Injection)